Drug Type Bispecific antibody |
Synonyms Humanized Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationRare Pediatric Disease (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteogenesis Imperfecta | Phase 1 | US | 03 Oct 2023 |